Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia

Drugs
G E PakesG S Avery

Abstract

Triazolam is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states. As triazolam has a relatively short half-life of about 2 to 3 hours in healthy subjects and has only 1 short acting active metabolite, alpha-hydroxytriazolam, it would seem more suitable as an hypnotic than longer acting drugs such as flurazepam, nitrazepam or flunitrazepam, particularly when residual sedative effects on the day after ingestion are undesirable. Thus, with usual hypnotic doses of triazolam (0.25 or 0.5 mg) impairment of psychomotor and cognitive function is generally not carried over into the day after ingestion, although at doses of 1 mg or greater, residual effects may appear. In short term comparative studies triazolam was clearly superior to a placebo, and was at lest as effective as flurazepam, or other benzodiazepines such as nitrazepam or diazepam, in hastening sleep onset, reducing nocturnal awakenings, and increasing sleep duration. In other studies it was often superior to chloral hydrate, methyprylone or quinalbarbitone (secobarbital). In a small number of patients with chronic insomnia receivin...Continue Reading

Citations

Dec 12, 1991·The New England Journal of Medicine
Jan 1, 1990·Journal of Psychoactive Drugs·V L Martin
May 1, 1989·Journal of the American Geriatrics Society·R J Sullivan
Apr 1, 1986·Acta Anaesthesiologica Scandinavica·O K RoaldJ D Michenfelder
Jan 1, 1988·Psychological Medicine. Monograph Supplement·A HiggittM Lader
Jan 1, 1988·Journal of Clinical Pharmacology·D J McClureJ C Pecknold
Aug 18, 1983·The New England Journal of Medicine·D J GreenblattD R Abernethy
Jan 1, 1983·European Journal of Clinical Pharmacology·O DehlinR B Smith
Mar 1, 1983·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
Dec 1, 1983·British Journal of Clinical Pharmacology·H R OchsM Knüchel
Feb 1, 1986·Journal of Clinical Pharmacology·R B SmithJ P Phillips
Jun 13, 1991·The New England Journal of Medicine·D J GreenblattR I Shader
Sep 17, 1987·The New England Journal of Medicine·D J GreenblattR I Shader
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·P D Kroboth, R P Juhl
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·C R SoldatosC N Stefanis
Sep 1, 1993·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·V K KontinenJ Sarvela
Dec 1, 1984·Drug Intelligence & Clinical Pharmacy·W A Parker, R A MacLachlan
Jun 1, 1987·British Journal of Clinical Pharmacology·H R OchsE S Burstein
Mar 1, 1988·Journal of Clinical Pharmacology·H FriedmanR I Shader
Oct 31, 2002·Human Psychopharmacology·Alain PatatIan Hindmarch
May 7, 2004·Neuroreport·Karen A MaubachGuy R Seabrook
Jan 18, 2006·Journal of Clinical Psychopharmacology·D J Greenblatt
May 30, 2007·Clinical Drug Investigation·Mario Giovanni TerzanoMembers of the Advisory Board
Aug 18, 2009·Journal of Sleep Research·Peter T MorganRobert T Malison
Jan 1, 1983·British Journal of Clinical Pharmacology·W H ZieglerM Eckert
Jan 1, 1983·British Journal of Clinical Pharmacology·R JochemsenD D Breimer
Jan 1, 1983·Psychopharmacology·D R AbernethyR I Shader
Jun 1, 1994·Scandinavian Journal of Primary Health Care·J Rosenberg, F Ahlstrøm
Dec 17, 2019·Biomolecules & Therapeutics·Hye Jin JeeYi-Sook Jung
Jan 1, 1988·Journal of Toxicology. Clinical Toxicology·D PerrotJ Motin
May 1, 1983·Pharmacotherapy·T RothF J Zorick
Jan 1, 1983·British Journal of Clinical Pharmacology·M MamelakV Price
Dec 26, 2008·Journal of Biomolecular Structure & Dynamics·Biswarup SahaParimal Karmakar
Jun 17, 1999·Journal of Dental Research·M RaadalH W Karl
Aug 1, 1983·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·J M CleghornP Szatmari
Jul 1, 1984·Postgraduate Medicine·R Malcolm, J A Gross

Related Concepts

Metazoa
Clinical Trials
Cognition
Transient Insomnia
Sleep Stages
Anti-Anxiety Effect
Trilam

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.